Back to Search Start Over

The evidence-based role of catecholaminergic PET tracers in Neuroblastoma. A systematic review and a head-to-head comparison with mIBG scintigraphy.

Authors :
Piccardo, Arnoldo
Treglia, Giorgio
Fiz, Francesco
Bar-Sever, Zvi
Bottoni, Gianluca
Biassoni, Lorenzo
Borgwardt, Lise
de Keizer, Bart
Jehanno, Nina
Lopci, Egesta
Kurch, Lars
Massollo, Michela
Nadel, Helen
Roca Bielsa, Isabel
Shulkin, Barry
Vali, Reza
De Palma, Diego
Cecchin, Diego
Santos, Ana Isabel
Zucchetta, Pietro
Source :
European Journal of Nuclear Medicine & Molecular Imaging. Feb2024, Vol. 51 Issue 3, p756-767. 12p.
Publication Year :
2024

Abstract

Background: Molecular imaging is pivotal in staging and response assessment of children with neuroblastoma (NB). [123I]-metaiodobenzylguanidine (mIBG) is the standard imaging method; however, it is characterised by low spatial resolution, time-consuming acquisition procedures and difficult interpretation. Many PET catecholaminergic radiotracers have been proposed as a replacement for [123I]-mIBG, however they have not yet made it into clinical practice. We aimed to review the available literature comparing head-to-head [123I]-mIBG with the most common PET catecholaminergic radiopharmaceuticals. Methods: We searched the PubMed database for studies performing a head-to-head comparison between [123I]-mIBG and PET radiopharmaceuticals including meta-hydroxyephedrine ([11C]C-HED), 18F-18F-3,4-dihydroxyphenylalanine ([18F]DOPA) [124I]mIBG and Meta-[18F]fluorobenzylguanidine ([18F]mFBG). Review articles, preclinical studies, small case series (< 5 subjects), case reports, and articles not in English were excluded. From each study, the following characteristics were extracted: bibliographic information, technical parameters, and the sensitivity of the procedure according to a patient-based analysis (PBA) and a lesion-based analysis (LBA). Results: Ten studies were selected: two regarding [11C]C-HED, four [18F]DOPA, one [124I]mIBG, and three [18F]mFBG. These studies included 181 patients (range 5–46). For the PBA, the superiority of the PET method was reported in two out of ten studies (both using [18F]DOPA). For LBA, PET detected significantly more lesions than scintigraphy in seven out of ten studies. Conclusions: PET/CT using catecholaminergic tracers shows superior diagnostic performance than mIBG scintigraphy. However, it is still unknown if such superiority can influence clinical decision-making. Nonetheless, the PET examination appears promising for clinical practice as it offers faster image acquisition, less need for sedation, and a single-day examination. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
16197070
Volume :
51
Issue :
3
Database :
Academic Search Index
Journal :
European Journal of Nuclear Medicine & Molecular Imaging
Publication Type :
Academic Journal
Accession number :
174879055
Full Text :
https://doi.org/10.1007/s00259-023-06486-9